The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical ...
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at ...
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, ...
New rapid sterility testing capability provides eligible products with results in approximately 3–7 days through automated, ...
The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox ...
VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but ...
Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strateg ...
The Shaoxing facility will provide 250 m³ of reaction volume, with potential capacity exceeding 400 m³, as the CDMO expands ...
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent ...
Specifying synthetic peptides: why the impurity profile, not the purity figure, is the specification
A single HPLC percentage can’t tell two peptide lots apart. A specification that names impurity classes, sets individual ...
GmbH has launched mzassist, a vendor-neutral AI and automation control layer for multimodal mass spectrometry data processing ...
The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results